MicroRNA‑148a inhibition protects against ovariectomy‑induced osteoporosis through PI3K/AKT signaling by estrogen receptor α

Xiao,Yu; Li,Bing; Liu,Jun

doi:10.3892/mmr.2018.8845

MicroRNA‑148a inhibition protects against ovariectomy‑induced osteoporosis through PI3K/AKT signaling by estrogen receptor α

Authors:
- Yu Xiao
- Bing Li
- Jun Liu
View Affiliations

Affiliations: Department of Joint Surgery, Tianjin Hospital, Tianjin 300211, P.R. China
Published online on: April 5, 2018 https://doi.org/10.3892/mmr.2018.8845
Pages: 7789-7796

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the effect of microRNA‑148a downregulation on osteoporosis by using an ovariectomized rat model. Reverse transcription‑quantitative polymerase chain reaction was used to analyze microRNA‑148a expression levels, MTT and flow cytometry assays were used to examine cytotoxicity and apoptosis, respectively. The gap‑associated proteins were quantified using western blotting. The expression of microRNA‑148a was significantly increased in osteoporosis rat following ovariectomy. Overexpression of microRNA‑148a significantly promoted apoptosis and inhibited cell growth, whereas downregulation of microRNA‑148a significantly reduced apoptosis and increased cell growth. Overexpression of microRNA‑148a significantly reduced estrogen receptor a (ERα) protein expression and suppressed phosphoinositide‑3‑kinase regulatory subunit 1 (PI3K) and phosphorylated‑protein kinase B (AKT) protein expression in osteoblasts in vitro. The inhibition of ERα increased the microRNA‑148a effect on apoptosis in osteoblasts in vitro. Subsequently, LY294002, an PI3K inhibitor, significantly increased the effect of microRNA‑148a on apoptosis in osteoblasts in vitro. The findings of the present study revealed that anti‑microRNA‑148a protected cells against ovariectomy‑induced osteoporosis through ERα by PI3K/AKT signaling.

View Figures

View References

1	Krantz E, Trimpou P and Landin-Wilhelmsen K: Effect of growth hormone treatment on fractures and quality of life in postmenopausal osteoporosis: A 10-year follow-up study. J Clin Endocrinol Metab. 100:3251–3259. 2015. View Article : Google Scholar : PubMed/NCBI
2	Hansen KE, Nabak AC, Johnson RE, Marvdashti S, Keuler NS, Shafer MM and Abrams SA: Isotope concentrations from 24-h urine and 3-h serum samples can be used to measure intestinal magnesium absorption in postmenopausal women. J Nutr. 144:533–537. 2014. View Article : Google Scholar : PubMed/NCBI
3	Sugimoto T, Nakamura T, Nakamura Y, Isogai Y and Shiraki M: Profile of changes in bone turnover markers during once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis. Osteoporos Int. 25:1173–1180. 2014. View Article : Google Scholar : PubMed/NCBI
4	Bonnick S, De Villiers T, Odio A, Palacios S, Chapurlat R, DaSilva C, Scott BB, Le Bailly De Tilleghem C, Leung AT and Gurner D: Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: A randomized placebo-controlled trial. J Clin Endocrinol Metab. 98:4727–4735. 2013. View Article : Google Scholar : PubMed/NCBI
5	Liu HF, He HC, Yang L, Yang ZY, Yao K, Wu YC, Yang XB and He CQ: Pulsed electromagnetic fields for postmenopausal osteoporosis and concomitant lumbar osteoarthritis in southwest China using proximal femur bone mineral density as the primary endpoint: Study protocol for a randomized controlled trial. Trials. 16:2652015. View Article : Google Scholar : PubMed/NCBI
6	Ruixo Pérez JJ, Zheng J and Mandema JW: Similar relationship between the time course of bone mineral density improvement and vertebral fracture risk reduction with denosumab treatment in postmenopausal osteoporosis and prostate cancer patients on androgen deprivation therapy. J Clin Pharmacol. 54:503–512. 2014. View Article : Google Scholar : PubMed/NCBI
7	Stuss M, Rieske P, Cegłowska A, Stêpień-Kłos W, Liberski PP, Brzeziańska E and Sewerynek E: Assessment of OPG/RANK/RANKL gene expression levels in peripheral blood mononuclear cells (PBMC) after treatment with strontium ranelate and ibandronate in patients with postmenopausal osteoporosis. J Clin Endocrinol Metab. 98:E1007–E1011. 2013. View Article : Google Scholar : PubMed/NCBI
8	Bai P, Sun Y, Jin J, Hou J, Li R, Zhang Q and Wang Y: Disturbance of the OPG/RANK/RANKL pathway and systemic inflammation in COPD patients with emphysema and osteoporosis. Respir Res. 12:1572011. View Article : Google Scholar : PubMed/NCBI
9	Baek JM, Kim JY, Yoon KH, Oh J and Lee MS: Ebselen is a potential anti-osteoporosis agent by suppressing receptor activator of nuclear factor kappa-B ligand-induced osteoclast differentiation in vitro and lipopolysaccharide-induced inflammatory bone destruction in vivo. Int J Biol Sci. 12:478–488. 2016. View Article : Google Scholar : PubMed/NCBI
10	Li H, Li T, Fan J, Li T, Fan L, Wang S, Weng X, Han Q and Zhao RC: miR-216a rescues dexamethasone suppression of osteogenesis, promotes osteoblast differentiation and enhances bone formation, by regulating c-Cbl-mediated PI3K/AKT pathway. Cell Death Differ. 22:1935–1945. 2015. View Article : Google Scholar : PubMed/NCBI
11	Yuan FL, Xu RS, Jiang DL, He XL, Su Q, Jin C and Li X: Leonurine hydrochloride inhibits osteoclastogenesis and prevents osteoporosis associated with estrogen deficiency by inhibiting the NF-κB and PI3K/Akt signaling pathways. Bone. 75:128–137. 2015. View Article : Google Scholar : PubMed/NCBI
12	Hao L, Fu J, Tian Y and Wu J: Systematic analysis of lncRNAs, miRNAs and mRNAs for the identification of biomarkers for osteoporosis in the mandible of ovariectomized mice. Int J Mol Med. 40:689–702. 2017. View Article : Google Scholar : PubMed/NCBI
13	Chen J, Qiu M, Dou C, Cao Z and Dong S: MicroRNAs in bone balance and osteoporosis. Drug Dev Res. 76:235–245. 2015. View Article : Google Scholar : PubMed/NCBI
14	Li H, Wang Z, Fu Q and Zhang J: Plasma miRNA levels correlate with sensitivity to bone mineral density in postmenopausal osteoporosis patients. Biomarkers. 19:553–556. 2014. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Brixen K, Chapurlat R, Cheung AM, Keaveny TM, Fuerst T, Engelke K, Recker R, Dardzinski B, Verbruggen N, Ather S, et al: Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: A randomized trial. J Clin Endocrinol Metab. 98:571–580. 2013. View Article : Google Scholar : PubMed/NCBI
17	Binkley N, Bolognese M, Sidorowicz-Bialynicka A, Vally T, Trout R, Miller C, Buben CE, Gilligan JP and Krause DS: Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) Investigators: A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: The Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial. J Bone Miner Res. 27:1821–1829. 2012. View Article : Google Scholar : PubMed/NCBI
18	Ma Y, Shan Z, Ma J, Wang Q, Chu J, Xu P, Qin A and Fan S: Validation of downregulated microRNAs during osteoclast formation and osteoporosis progression. Mol Med Rep. 13:2273–2280. 2016. View Article : Google Scholar : PubMed/NCBI
19	Jiang ZS and Hao ZH: An insertion/deletion polymorphism within the 3′-untranslated region of COL1A2 confers susceptibility to osteoporosis. Mol Med Rep. 14:4415–4421. 2016. View Article : Google Scholar : PubMed/NCBI
20	Zhang D, Maalouf NM, Adams-Huet B, Moe OW and Sakhaee K: Effects of sex and postmenopausal estrogen use on serum phosphorus levels: A cross-sectional study of the National Health and Nutrition Examination Survey (NHANES) 2003–2006. Am J Kidney Dis. 63:198–205. 2014. View Article : Google Scholar : PubMed/NCBI
21	Martynetz FA, Pessole Biondo-Simões Mde L, Martynetz JR, Martynetz TD, Zimerman E and Neto HM: Tomografic and tensiometric assessment on femurs from oophorectomized rats subjected to hormone replacement therapy. Rev Bras Ortop. 45:40–45. 2015. View Article : Google Scholar : PubMed/NCBI
22	Sanders S and Geraci SA: Osteoporosis in postmenopausal women: Considerations in prevention and treatment: (women's health series). South Med J. 106:698–706. 2013. View Article : Google Scholar : PubMed/NCBI
23	Ma F, Feng Y, Li W, Li Z, Liu T and Li L: miR-148a suppresses estrogen-induced viability and migration of breast cancer cells via inhibition of estrogen receptor α expression. Exp Ther Med. 13:2515–2522. 2017. View Article : Google Scholar : PubMed/NCBI
24	Zhang H, Wang Y, Xu T, Li C, Wu J, He Q, Wang G, Ding C, Liu K, Tang H and Ji F: Increased expression of microRNA-148a in osteosarcoma promotes cancer cell growth by targeting PTEN. Oncol Lett. 12:3208–3214. 2016. View Article : Google Scholar : PubMed/NCBI
25	Ge P, Cui Y, Liu F, Luan J, Zhou X and Han J: L-carnitine affects osteoblast differentiation in NIH3T3 fibroblasts by the IGF-1/PI3K/Akt signalling pathway. Biosci Trends. 9:42–48. 2015. View Article : Google Scholar : PubMed/NCBI